Biomarkers such as pregnancy-associated plasma protein A (PAPP-A), placental protein 13 (PP13), cell-free DNA (cfDNA), sex-hormone binding globulin (SHBG), follistatin, and myostatin show promise in predicting GDM, with varying sensitivities [64,65]. This evidence concerns the gene LGALS13 and gestational diabetes.